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of a Clinical Risk Score in
Aninternational Cohort’’
To the Editors:
We read with great interest the article byZheng et al,1 which validated the abil-
ity of a previously reported clinical risk
score2 in predicting recurrence patterns and
incidences after surgical resection of hepa-
tocellular carcinoma (HCC). A creative
classification was proposed by the authors
to distinguish patients with postoperative
HCC recurrence into 2 patterns, those within
and those beyond the Milan Criteria. Such a
classification would be of great value in
assessing the feasibility of further curative
resections for patients with HCC recurrence.
It is essential to identify potential markers
and factors that are associated with a higher
risk of developing recurrent HCC beyond
the Milan Criteria postoperatively. Con-
sequently, more rigorous surveillance and
screening strategies (eg, with shorter inter-
vals and more prolonged periods) are necess-
ary for high-risk patients. There may even be
a role to study experimental antirecurrence
treatment modalities. We appreciate the
authors’ excellent work. However, we would
like to raise the following comments.
First, in this study, a detailed follow-
up program of recurrence surveillance for the
included patients was not provided by the
authors. We believe that a good recurrence
surveillance strategy has a substantial impact
on the patterns of recurrence (within or
beyond the Milan Criteria). If postoperative
recurrence is detected early (within the
Milan Criteria), curative therapies such as
re-resection, radiofrequency ablation, or liver
transplantation are still the possible treatment
options for these patients with recurrent
HCC. Many hepatic centers recommend 2
to 3 months to be the optimal time interval for
postoperative follow-up for patients after
curative resection of HCC. In our center,
we generally recommend patients to undergo
ultrasound and serum alpha fetoprotein once
every 1 to 2 months for the first 6 months
after resection, then once every 3 months
thereafter. This strategy is based on our
observation that the early recurrence rate
(<2 yrs) is much higher than the late recur-
rence rate (>¼ 2 yrs). Unfortunately, not all
our patients would stick to this follow-up
protocol. Some patients would not come back
to see us until they develop symptoms of
recurrent tumors. Our experience showed
that HCC recurrence in patients who had
regular recurrence surveillance were more
likely to have their recurrence detected at
an early stage, that is within the Milan
Criteria, while those patients who did not
have regular follow-up were more likely to
have tumor recurrence beyond the Milan
Criteria. Hence, the interval of recurrence
surveillance is of great significance to the
recurrence patterns (within or beyond the
Milan Criteria).3,4 We failed to find this
important information in the reported study.
Second, the influence of the diagnostic
tests used in recurrence surveillance on the
recurrence patterns would also be important.
In general, most centers would use abdominal
ultrasound and a serologic alpha-fetoprotein
test. For patients with clinically suspected
HCC recurrence, cross-sectional images
including computed tomography or magnetic
resonance imaging would be added. Such tests
were neither reported in the study.
As we think, clarification regarding the
above-mentioned omissions would greatly
consolidate the conclusions of their study.
This work was supported in part by the
National Natural Science Foundation of
China (Nos. 81472284 and 81672699).
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Validation of a Clinical Risk
Score in Aninternational
Cohort’’
D ear Dr Yu et al,Our study validated a clinical risk
score to predict recurrence following resection
of hepatocellular carcinoma (HCC).1 Thank
you for asking these very important and
insightful questions about the impact of sur-
veillance practice on the recurrence pattern
following these curative intent resections. The
National Comprehensive Cancer Network
(NCCN) guideline recommends cross-
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sectional imaging at 3 to 6-month intervals for
the first 2 years and then every 6 to 12 months
thereafter.2 In addition, if patients had elevated
preoperative alpha-fetoprotein (AFP), they
should be measured every 3 months for 2 years
postoperatively, and then every 6 months
thereafter. As our study included 5 different
institutions spanning North America, Europe,
and Asia, the practice may vary slightly
depending on insurance coverage under differ-
ent health care systems, institutional resour-
ces, and patients’ social factors.
At Memorial Sloan Kettering Cancer
Center, we evaluate patients within 2 weeks
postoperatively, then follow them every 3 to
4 months in the first 2 years, and then every
6 months thereafter. For surveillance studies,
we utilized AFP and liver function tests, and
serial computed tomography (CT) scan and/
or magnetic resonance imaging (MRI) as per
NCCN guideline.3 In addition, we have a
Cancer Registry that contacts patients and
their providers annually to obtain updated
disease status for our prospectively main-
tained database. During surveillance, when
there is a question of recurrence, we review
patients’ clinical and radiologic information
at our weekly Disease Management Team
meeting, which are well attended by surgical
oncologists, radiologists, medical and radi-
ation oncologists, gastroenterologists, inter-
ventional radiologists, and pathologists.
At Washington University at St. Louis
and at University of Montreal in Canada, the
surveillance practices are as recommended
by NCCN. Similarly, at Erasmus Medical
Center in the Netherlands, patients were fol-
lowed postoperatively with CT or MRI com-
bined with serum AFP at 3 to 6 month
intervals for up to 2 years, and then followed
by annually for up to 5 years.4
At Singapore General Hospital and
National Cancer Center in Singapore, the first
follow-up posthepatectomy is usually in about
2 weeks to review postoperative recovery, and
thereafter for HCC surveillance. Patients were
followed at intervals of 3 to 6 months for the
first 2 years and then at 6 to 12 monthly
intervals as per NCCN guideline. Clinical
surveillance consisted of clinical evaluations,
serial AFP, and hepatic imaging using ultra-
sound, CT scan, or MRI as deemed appropri-
ate by the surgeon. Of note, as these centers are
tertiary referral centers, there are a substantial
number of patients who travel from afar for
resection and then receive follow-up with their
local hepatologists. For example, medical
tourism is a major component in Singapore
as medical care is better than some of the
neighboring Southeast Asian countries. This
may affect median length of follow-up or
frequency of follow-up, but the median fol-
low-up was 4.5 years among Singaporean
cohort.
The impact of surveillance practice on
recurrence pattern following resection of
HCC is indeed a crucial question to address
and should be further studied. In this study,
we did not evaluate this question but it will be
an important pursuit to evaluate the impact of
the frequency and total length of serial imag-
ing on earlier detection of HCC. However,
given what we know about HCC growth
kinetics, it would seem unlikely that differ-
ences in the timing of imaging studies of a
few weeks or even a few months would
ultimately change the findings, treatment,
or prognosis for most patients. The actual
impact will be further investigated. Thank
you for your thoughtful comments on this
letter to the editor.
This work was supported in part by
NIH/NCI P30 CA008748 Cancer Center Sup-
port Grant.
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Comment on ‘‘Does a
Combination of
Laparoscopic Approach





We read with great interest the article byLe’on Maggiori et al.1 In order to
assess the postoperative outcomes of combi-
nation of laparoscopic approach and full fast
track multimodal (FFT) management, the
authors assigned patients with colorectal cancer
into 2 groups: FFT and LFT (limited fast track
program), the latter of which was established as
a control. No differences in length of stay (LOS)
or postoperative morbidity were, however,
obtained between the 2 groups in that study.
The fast track (FT) care program, also
known as Enhanced Recovery After Surgery
(ERAS) program, is a multimodal approach
that aims to minimize the physiologic impact
of surgery and anesthesia.2 As recommended
by several guidelines with regard to clinical
practice of ERAS protocol in perioperative
management, there are 15 to 25 recom-
mended items that might contribute to the
improvement of clinical outcome.3–5 The
relative significance of each element, how-
ever, remains unknown because of the lack of
definitive support from evidence-based
medicine.6 Moreover, the complete imple-
mentation of all these recommended items,
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